PPCB

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Retrieved on: 
Thursday, February 22, 2024

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.
  • The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel, and melanoma) after treatment with a rectal formulation of pancreatic proenzymes.
  • Nineteen of 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than the expected life span (mean survival of 9.0 months vs life expectancy of 5.6 months), with no severe or serious adverse events related to administration.

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Retrieved on: 
Tuesday, January 16, 2024

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.
  • The foundation patent covers composition claims for the Company’s lead product candidate, PRP.
  • The Canadian foundation patent is the final application to receive a certificate of grant in the Company’s foundation patent family (there are two divisional patents remaining citing additional inventions in the US and Mexico further dividing an original patent,).
  • This means that grant status has been secured in every jurisdiction in which the Company has filed a foundation patent application.

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

Retrieved on: 
Monday, December 18, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.
  • As part of the process, the opportunity to consider up-listing to a national US stock exchange will also be considered.
  • The emerging boutique advisory firm currently has a $3B+ transaction history and access to a global network of investors the Company intends to fully utilize.
  • PRP, a combination of two proenzymes trypsinogen and chymotrypsinogen, is a novel, targeted therapy for the treatment and prevention of metastatic cancer.

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

Retrieved on: 
Wednesday, December 13, 2023

Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.

Key Points: 
  • Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
  • “Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer.
  • But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer.
  • Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer.

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

Retrieved on: 
Tuesday, August 15, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.
  • This includes the finished drug product manufacture and validation of the bioanalytical method to analyze the pharmacokinetics (movement of drug within the body) of PRP during the study.
  • The Peter Mac Cancer Center is a world leading cancer research, education and treatment center and Australia’s only public health service dedicated to caring for people affected by cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030

Retrieved on: 
Tuesday, July 25, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s clinical candidate PRP targeting the pancreatic cancer market is forecast to reach $6.93 Billion by 2030, according to a report published by The Brainy Insights, a market research company.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s clinical candidate PRP targeting the pancreatic cancer market is forecast to reach $6.93 Billion by 2030, according to a report published by The Brainy Insights, a market research company.
  • According to the report, the global pancreatic cancer market is expected to grow at a compound annual growth rate (CAGR) of 8.13% during the forecast period between 2022 to 2030.
  • As a result of laboratory and clinical studies undertaken in pancreatic cancer, Propanc applied for and received Orphan Drug Designation from the US FDA for the use of PRP to treat pancreatic cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

Retrieved on: 
Thursday, July 13, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.
  • The EMT is a mechanism by which cancerous cells become motile and invasive, as well as immortal, thus seeding new tumors.
  • We have published scientific and clinical data in peer reviewed journals providing evidence that PRP can become an effective tool in the fight against cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (US FDA) for treatment of pancreatic cancer.

Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

Retrieved on: 
Wednesday, July 5, 2023

The program is designed to produce a backup clinical compound to the Company’s lead product candidate, PRP, which is from bovine origin, targeting metastatic cancer from solid tumors.

Key Points: 
  • The program is designed to produce a backup clinical compound to the Company’s lead product candidate, PRP, which is from bovine origin, targeting metastatic cancer from solid tumors.
  • According to Emergen Research, the global metastatic cancer market is projected to be worth over $111 Billion by 2027.
  • Furthermore, cell viability assays on pancreatic cancer stem cells (Bx PC3-CSCs) suggest that recombinant proenzymes may possess an even stronger anti-tumor effect than pancreatic proenzymes from bovine origin.
  • It started with a comprehensive assessment of our current level of understanding of proenzymes and then describes in detail recombinant technology, culminating in the successful production of a completely synthetic recombinant product.

Propanc Biopharma Provides Shareholder Update

Retrieved on: 
Thursday, June 22, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.
  • Propanc recently filed a post-effective Form S-1 amendment on behalf the lead investor who has funded approximately $2.25 million to date.
  • Propanc plans to compile the Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in 2023.
  • To date, Propanc has raised approximately $23 million dollars, culminating in the Company’s lead asset ready to commence clinical development, and a backup clinical compound entering preclinical stage.